Insta
Clinical Trial Of Anti-Leprosy Drug On Covid-19 Patients Yielding Good Results, Claims AIIMS Bhopal
Swarajya Staff
May 16, 2020, 03:05 PM | Updated 03:05 PM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
The All India Institute of Medical Sciences (AIIMS) Bhopal, which was allowed by the Drug Controller General of India (DCGI) to conduct clinical trials of an anti-leprosy drug on Covid-19 patients, has claimed that the treatment with the drug has yielded some good results, reports Economic Times.
According to the report, the institute has conducted trials of the drug Mycobacterium W (Mw) on Covid-19 patients at AIIMS Bhopal for the last few days.
"So far, three COVID-19 patients have recovered after the clinical trial of Mycobacterium W (Mw) at AIIMS," director of the institute Dr Sarman Singh was quoted in the report as saying.
He said that that the trials were being run for the last few days and the results were good as three out of the four patients enrolled for the trial had fully recovered and were discharged.
Dr Singh added that if the Mycobacterium W proves effective during the clinical trial, it will be used in the treatment of Covid-19.
The Mycobacterium W is used in the treatment of leprosy. The Council for Scientific and Industrial Research (CSIR) has recently tied up with Cadila pharmaceuticals to evaluate the effect of this drug for faster recovery of hospitalised Covid-19 patients, Singh said.
Earlier in April, the DCGI had granted permission to the CSIR to conduct tests of the Mw on critically ill Covid-19 patients at three hospitals in the country - AIIMS Delhi, AIIMS Bhopal and PGI Chandigarh.
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.